Arcus Biosciences, Inc. - RCUS STOCK NEWS

Arcus Biosciences, Inc. (NYSE:RCUS) announced the granting of stock options and restricted stock units to nine new employees. A total of 34,000 options at an exercise price of $17.36 per share and 15,200 restricted stock units were issued. The options were granted under the company’s 2020 Inducement Plan, which was approved in January 2020.

Arcus is focused on developing innovative therapies for cancer treatment, examining molecules targeting various biological pathways. Founded in 2015, it currently has six investigational medicines in clinical studies.

Arcus Biosciences (NYSE:RCUS) announced the grant of stock options and restricted stock units to eight new employees as part of its 2020 Inducement Plan. A total of 66,200 options were granted at an exercise price of $17.78, the closing price on March 8, 2023, along with 33,100 restricted stock units. This move aims to attract talent in the clinical-stage biopharmaceutical sector, focusing on innovative therapies for cancer treatment. Founded in 2015, Arcus is advancing six investigational drugs targeting various cancer pathways.

Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company, announced participation in a fireside chat at the Barclays Global Healthcare Conference on March 14, 2023, at 8:30 a.m. ET in Miami Beach, Florida. The chat will be accessible via live webcast through the Investors & Media section of the Arcus website.

Founded in 2015, Arcus focuses on developing innovative therapies for cancer, including investigational drugs targeting TIGIT and PD-1. The company aims to enhance the efficacy of cancer treatment through unique biological combinations.

Arcus Biosciences reported Q4 and full-year 2022 financial results, highlighting a net loss of $67 million for Q4 and $267 million for the full year. Revenues dropped to $34 million in Q4, down from $355 million in the previous year. The firm holds $1.1 billion in cash and equivalents, sufficient to fund operations into 2026. Domvanalimab, their lead molecule, has shown promising results in ongoing Phase 3 studies, particularly in non-small cell lung cancer (NSCLC), with median progression-free survival extending to 12 months. Updates on clinical studies and further data presentations are expected throughout 2023.

Arcus Biosciences (NYSE:RCUS) has granted stock options to three new employees, totaling 7,000 shares at an exercise price of $18.66, the closing price on February 23, 2023. Additionally, restricted stock units were awarded for 3,500 shares. These grants fall under the 2020 Inducement Plan approved in January 2020 and adhere to NYSE rules. Arcus is a clinical-stage biopharmaceutical firm focused on innovative cancer therapies, developing six investigational medicines targeting various biological pathways.

Arcus Biosciences (NYSE:RCUS) announced the granting of stock options and restricted stock units to eight new employees. A total of 31,600 shares were allocated at an exercise price of $20.68, based on the closing price on February 8, 2023. Additionally, 15,800 shares in restricted stock units were granted. These equity awards were issued under the Company’s 2020 Inducement Plan, approved in January 2020. This move aims to enhance recruitment and retention of talent in their ongoing efforts to develop innovative cancer therapies.

Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company, announced participation in two virtual investor events in February 2023. The events include the SVB Securities Virtual Global Biopharma Conference on February 14 at 12:00 p.m. ET, and Citi’s 2023 Virtual Oncology Leadership Summit on February 21 at 1:00 p.m. ET. Both will feature fireside chats from the management team. Webcasts will be accessible through the “Investors & Media” section of the Arcus Biosciences website, with replays available post-event. The company is focused on developing innovative cancer therapies and has advanced six investigational medicines into clinical studies.

Arcus Biosciences (NYSE:RCUS) announced the granting of stock options and restricted stock units to ten new employees. The options allow the purchase of 44,300 shares at an exercise price of $22.02, the closing price on January 23, 2023. Additionally, 22,150 shares in restricted stock units were granted. These equity awards fall under the Company’s 2020 Inducement Plan, approved in January 2020. Arcus, founded in 2015, focuses on developing innovative cancer therapies, having advanced six investigational medicines into clinical studies targeting various cancer-related pathways.

Gilead Sciences (GILD) and Arcus Biosciences (RCUS) reported positive interim results from the ARC-7 study, a Phase 2 trial in patients with first-line metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression. Both doublet and triplet therapy arms containing domvanalimab showed a 35-45% reduction in the risk of progression or death compared to zimberelimab monotherapy, with median progression-free survival (PFS) of 12.0 months for the doublet and 10.9 months for the triplet. Results will be showcased on December 20 during the ASCO Monthly Plenary Series.